Sydney, Nov 4, 2005 AEST (ABN Newswire) - Clinical Cell Culture Ltd (ASX: CCE) announced today that it has signed a Heads of Agreement with Sewon Cellontech Co. Ltd. (Cellontech - www.cellontech.com) for the local contract manufacturing of CellSpray(R) products for Korea. An investor conference call is scheduled, refer details below.
This is the first agreement of its type in the global rollout of CellSpray(R), with product to be manufactured under licence, distributed and marketed by established third parties.
The Korean CellSpray(R) strategy will focus on the contract manufacturing of CellSpray(R) products by Sewon Cellontech for the Korean market, with promotion, clinical support and logistic services being provided by AlloLife Corporate (AlloLife), C3's Korean ReCell(R) distributor.
Contact
John McGlue
Portal Novelli
Tel: +61 8 9386 1233
Mob: +61 417 926 915
| ||
|
